Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 154,773

Document Document Title
WO/2019/115812A1
The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflamm...  
WO/2019/118112A1
Oxygenases and methods of biologically upgrading hydrocarbon streams, such as crude oil, using oxygenases are provided herein. The oxygenases can be used to remove impurities such as metals, heteroatoms, or asphaltenes from a hydrocarbon...  
WO/2019/094669A3
Synthetic nanostructures, polypeptides that are useful, for example, in making synthetic nanostructures, and methods for using synthetic nanostructures are disclosed herein.  
WO/2019/083319A3
The present invention relates to a method for preparing a composition containing factor 8 (FVIII) capable of controlling the content of von Willebrand factor (vWF) and von Willebrand factor (vWF) and, more specifically, to a method for p...  
WO/2019/117976A1
This disclosure provides novel anionic amphiphilic β-hairpin peptides that self-assemble under appropriate conditions to form a reversible gel-sol hydrogel that can be used, for example, to readily deliver protein therapeutics and cells...  
WO/2019/116146A1
The present invention relates to the identification of a set of prognostic and theranostic markers enabling to assess the tumor microenvironment (immunogenic or immunosuppressive) of solid tumors and predict the responsiveness or the non...  
WO/2019/094725A3
The present disclosure is in the field of genome engineering, particularly targeted genetic modification of a CISH gene.  
WO/2019/115527A1
The invention relates to a peptidomimetic comprising or consisting of a D amino-acid sequence having at least 75% identity with SEQ ID NO: 1 or SEQ ID NO: 2, or variants or fragments thereof, in particular a peptidomimetic having the cap...  
WO/2019/114768A1
The present disclosure relates to genetically modified non-human animals that express a human or chimeric (e.g., humanized) CD3e (T-cell surface glycoprotein CD3 epsilon chain), and methods of use thereof.  
WO/2019/118689A1
The present invention relates to methods for enhancing recovery after an ischemic injury, including cerebral ischemia and stroke, by administration of therapeutic amounts of Domain V protein.  
WO/2019/118895A1
The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodefic...  
WO/2019/118508A1
The present disclosure provides modified immune cell (e.g., modified T cell) comprising an exogenous T cell receptor (TCR) having specificity for NY-ESO-1. The present disclosure provides modified immune cells or precursors thereof (e.g....  
WO/2019/118696A1
Disclosed herein are fusion proteins comprising a truncated thrombostasin protein having at least 85% sequence homology to a thrombostasin protein, wherein the thrombostasin protein has a carboxy terminal deletion; and a fusion partner p...  
WO/2019/118885A1
The present disclosure provides improved compositions for adoptive T cell therapies targeting NKG2D ligands for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory ...  
WO/2019/118548A1
This disclosure provides engineered strains of Corynebacteria for the cost-effective production of lysine, tools and methods used to produce the engineered strains, and methods of using the engineered strains to produce lysine.  
WO/2019/117399A1
The present application relates to a novel polypeptide which has the ability to release 5'-inosinic acid, a microorganism containing same, and a 5'-inosinic acid production method using same.  
WO/2019/118893A1
The present application describes stapled peptide degron chimeras, which act as protein degradation inducing moieties, either by combining a stapled peptide that binds a disease-related protein with a small molecule degron, such as a cer...  
WO/2019/118342A1
Compositions and methods are provided for genome modification of a nucleotide sequence located in or near a male fertility gene of Ms1 or Ms5 in the genome of a plant cell or plant to produce a male-sterile plant. In some examples, the m...  
WO/2019/118113A1
Dioxygenases and methods of biologically upgrading hydrocarbon streams, such as crude oil, using dioxygenases are provided herein. The dioxygenases can be used to remove impurities such as metals, heteroatoms, or asphaltenes from a hydro...  
WO/2019/114123A1
Provided in the present invention is a GnRH polypeptide antigen and a preparation method therefor. Further provided is a method for using the GnRH polypeptide antigen to prepare castration vaccines for animals.  
WO/2019/118949A1
The specification provides methods for introducing a desired genetic change in a nucleotide sequence using a double-strand break (DSB)-inducing genome editing system, the method comprising: identifying one or more available cut sites in ...  
WO/2019/113703A1
A combination prime:boost therapy is described herein. The combination therapy is for use in inducing an immune response in a mammal. The combination includes: an attenuated Listeria monocytogenes (LM) bacteria that is capable of express...  
WO/2019/115928A1
Composition comprising an aqueous liquid extract of phycobiliproteins, containing phycocyanin, which is obtained from cyanobacteria or micro-algae and which has not been subjected to any drying step, said composition being used to preven...  
WO/2019/116051A1
There is provided a plasmid system for transfection into a cell to create a producer cell, the system comprising: a. a helper plasmid comprising a first nucleotide sequence encoding Murine leukemia virus (MLV)-derived Gag and Pol poly-pr...  
WO/2019/067871A3
Contemplated compositions and methods use various immunomodulatory agents to downregulate an autoimmune response and/or to upregulate immune responses against autoantigen presenting cells.  
WO/2019/118358A1
Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.  
WO/2019/116392A1
The present invention provides methods and compositions to reduce growth of microbial colonies, including infections, and includes therapeutic compositions, methods for treatment of infections, and methods for identifying additional such...  
WO/2019/116046A1
The present invention relates to a cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) a chimeric TNF receptor (TNFR) which comprises (a) a binding domain which is capable of bindin...  
WO/2019/113711A1
Provided herein are fusion constructs including a biologically active agent such as an antibody or derivative thereof which is functionally linked with a functional moiety such as an LC3 protein or portion thereof. Also provided are comp...  
WO/2019/118719A1
This disclosure features structurally-stabilized and/or cysteine-reactive peptide inhibitors for selective targeting of BFL-1, or dual targeting of BFL-1 and MCL-1. Also disclosed are methods of using such structurally-stabilized and cys...  
WO/2019/115609A1
The present invention covers peptidic human Y1 receptor agonist - saccharide functionalised carbaborane conjugate compounds of general formula (I): X5PSX1PX6FPGX7X8X9PX10X11X12X13X2X14YYX3X15X16X17X4YINLITRPR Y-NH2, in which F, G, I, L, ...  
WO/2019/116357A1
This disclosure relates to a method for extracting keratin from animal hair, in particular from pigs hair, wherein the method comprises several steps, for example degreasing the animal hair with a solution of a degreaser and filtering th...  
WO/2019/118888A1
Provided herein are macrophages engineered for treating fibrosis and ameliorating the effects of fibrotic lesions in various organs and tissues. Certain embodiments are directed to genetically-engineered macrophages capable of treating f...  
WO/2019/118818A1
A fibronectin type III (FN3) domain-nanoparticle or direct conjugate complex containing a polynucleotide molecule, a toxin, polynucleotide molecule or other pharmaceutically active payload is obtained by panning an FN3 domain library wit...  
WO/2019/070517A9
Presented herein are systems and methods that provide for a biologic development determination technology that facilitates determining effective and improved procedures for developing biologics. In particular, in certain embodiments, the...  
WO/2019/115816A1
There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a )administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising...  
WO/2019/118918A1
CD19 variants, methods of identifying CD19 variants, and methods of using such CD19 variants, e.g., for treating cancer, are described.  
WO/2019/116342A1
It is here claimed an oligopeptide of sequence SJXXZGXP (SEQ ID no. 7), where S is a serine, J is a serine or it is absent, X is independently any desired amino acid, Z is selected from tyrosine, histidine, phenylalanine or tryptophan, G...  
WO/2019/113688A1
We have developed a series of Ebola virus envelope glycoprotein (EboGP)- based chimeric fusion proteins that are still able to maintain an efficient EboGP- mediated virus entry in various cell types including human antigen-presenting cel...  
WO/2019/118111A1
Nickel -binding proteins and methods of biologically upgrading hydrocarbon streams, such as crude oil, using nickel -binding proteins are provided herein. The nickel-binding proteins can be used to remove impurities such as metals and/or...  
WO/2019/113710A1
Disclosed are methods for converting a substrate into a product benzylisoquinoline compound in a biosynthetic system involving the culturing of cells in a medium. The cells comprise a benzylisoquinoline uptake permease and a biosynthetic...  
WO/2019/117296A1
Provided is a method for producing a molded product comprising: a step 1 for molding a composition containing a structural protein; and a step 2 for compressing and stretching the molded composition obtained in the step 1.  
WO/2019/117057A1
The present invention addresses the problem of providing a cell-membrane-permeable peptide capable of migrating into a cell. The present inventors have provided a cell-membrane-permeable peptide comprising the amino acid sequence represe...  
WO/2019/118771A1
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus LEMDl antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a muta...  
WO/2019/117673A2
The present invention relates to a new polypeptide having a 5'-inosine monophosphate discharging function, a microorganism having the same, a method for manufacturing 5'-inosine monophosphate using the same, and a method for increasing d...  
WO/2019/118475A1
The present invention pertains to engineered immortalized T-cell lines, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered immortalized T-cell lines of the invention are characterized...  
WO/2019/118701A1
This present patent application relates to a method for controlling a targeted gene expression with an environmental trigger useful for manufacturing a natural product or an analogue thereof biologically. In particular, the present inven...  
WO/2019/118518A2
The present disclosure provides inducible cell receptors and therapeutic cells comprising the inducible cell receptors. Further provided are methods of preparing the therapeutic cells and methods of treating a subject by administering th...  
WO/2019/118938A1
In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin anal...  
WO/2015/185067A9
The present invention describes the use of nucleic acid barcodes as specific labels for MHC multimers to determine the antigen responsiveness in biological samples. After cellular selection the barcode sequence will be revealed by sequen...  

Matches 1 - 50 out of 154,773